TABLE 3.
Vaccines against group C Salmonella currently licensed or in development
| Vaccine name | Type | Principle | Serovar(s) (serogroup) included | Usage | Company and/or reference |
|---|---|---|---|---|---|
| Licensed vaccinesa | |||||
| Nitro-Sal | Live attenuated | Chemical mutagenesis | Choleraesuis (C1) | Swine | Arko Laboratories (Jewel, IA, USA) |
| Nobl | Live attenuated | Loss of virulence plasmid | Choleraesuis (C1) | Swine | 51 |
| Argus-SC | Live attenuated | Gene deletions (Δcya and Δcrp) | Choleraesuis (C1) | Swine | 50 |
| Enterisol Salmonella T/C | Live attenuated | Public information not available | Choleraesuis (C1), Typhimurium (B) | Swine | Boehringer Ingelheim GmbH (Ingelheim, Germany) |
| Enterisol SC-54 | Live attenuated | Loss of virulence plasmid | Choleraesuis (C1) | Swine | Boehringer Ingelheim GmbH |
| Suisaloral | Live attenuated | Attenuating gene mutation | Choleraesuis (C1) | Swine | IDT Biologika GmbH (Desau-Roslau, Germany); 53 |
| Newport SRP | Component vaccine | Purified siderophore receptor and porin | Newport (C2) | Cattle | Zoetis Inc. (Florham Park, NJ, USA) |
| Vaccines in developmentb | |||||
| Salenvac | Killed vaccine | Inactivated whole-cell vaccine | Typhimurium (B), Mbandaka (C1), Orion (E) | Poultry | Intervet Schering-Plough Australia; 59 |
| Unknown | Killed vaccine (with adjuvant) | Inactivated whole-cell vaccine | Typhimurium (B), Infantis (C1), Enteritidis (D) | Poultry | 58 |
| TBD | Live attenuated | Attenuating gene deletions | Paratyphi C (C1), Newport (C2) | Human | F. J. Fuche and S. M. Tennant, Center for Vaccine Development (unpublished data) |
| TBD | Conjugate vaccine | Core O polysaccharide conjugated to flagellin | Paratyphi C (C1), Newport (C2) | Human | G. Ramachandran and R. Simon, Center for Vaccine Development (unpublished data) |
a
Data include vaccines with conditional licenses.
b
TBD, vaccine name to be determined.